Public biopharmaceutical company
Appears in 1 story
Acquired; delisted from Nasdaq; operates as a Vertex subsidiary
Vertex Pharmaceuticals closed its $10 billion acquisition of Crinetics Pharmaceuticals on September 1, 2026, the largest deal in the company's history. Crinetics shareholders received $85 per share in cash, and the San Diego biotech is now a wholly owned Vertex subsidiary.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
